923035-05-6

Basic information

• Product Name: Rivastigmine EP Impurity E
• Synonyms: Rivastigmine EP Impurity E;(S)-3-[1-(methylamino)ethyl]-phenyl N-ethyl-N-methyl-carbamate
• CAS NO: 923035-05-6
• Molecular Formula: C₁₃H₂₀N₂O₂
• Molecular Weight: 236.3101
• Mol File: 923035-05-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 321.3±34.0 °C(Predicted)
• Appearance: /
• Density: 1.044±0.06 g/cm3(Predicted)
• PKA: 9.28±0.10(Predicted)
• CAS DataBase Reference: Rivastigmine EP Impurity E(CAS DataBase Reference)
• NIST Chemistry Reference: Rivastigmine EP Impurity E(923035-05-6)
• EPA Substance Registry System: Rivastigmine EP Impurity E(923035-05-6)

Safety Data

• Hazardous Substances Data: 923035-05-6(Hazardous Substances Data)

Usage

Description

Rivastigmine EP Impurity E, also known as Namino-Desmethyl Rivastigmine, is an impurity found in Rivastigmine (R541000), a brain selective acetylcholinesterase inhibitor used for the treatment of mild to moderate dementia. It is a chemical byproduct that may be present during the synthesis or formulation of Rivastigmine.

Uses

Used in Pharmaceutical Industry:
Rivastigmine EP Impurity E is used as a reference standard for quality control and analytical testing in the pharmaceutical industry. It helps ensure the purity, potency, and safety of Rivastigmine medications by providing a benchmark for comparison during the development, manufacturing, and quality assurance processes.
Additionally, understanding the presence and effects of Rivastigmine EP Impurity E can aid in optimizing the synthesis and formulation of Rivastigmine, potentially improving its therapeutic efficacy and reducing any adverse effects associated with the presence of impurities.

Upstream product

• 1017234-25-1 3-[(1S)-1-{methyl[(1S)-1-phenylethyl]amino}ethyl]phenyl N-ethyl-N-methylcarbamate 
• 894079-42-6 3-[(S)-1-(methylamino)ethyl]phenol 
• 42252-34-6 N-ethyl-N-methylcarbamoyl chloride 

Downstream Products

• 123441-03-2 rivastigmin 

Relevant articles and documents

PREPARATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES

The present invention provides N-methylethylcarbamino-3-[(S)-1-(methyl-[(S)-1-phenylethyl] amino) ethyl] phenyl ester represented by formula (II) and its preparation method. The present invention also provides (S)-1-(3-methoxyphenyl)-N-methyl-N-[(S)-1-phenylethyl] ethylamine and 3-[(S)-1-(methyl-[(S)-1-phenylethyl] amino) ethyl] phenol as intermediates of the compound represented by formula (II), and the use of the compound represented by formula (II) for preparing rivastigmine used for treating Alzheimer disease.

METHOD OF OBTAINING PHENYL CARBAMATES

The invention relates to a method of obtaining phenyl carbamates (I), wherein R 1 is lower alkyl C 1 -C 5 or benzyl and R 2 is methyl, ethyl or propyl, consisting in reacting L-(S)-3-[(1-methylamino)ethyl]phenol, in the presence of a base, with a carbamoyl halide in order to obtain an intermediate and, subsequently, subjecting said intermediate to a reducing amination reaction or a methylation reaction by reacting same with a methyl halide. The above-mentioned compounds (I) include rivastigmine, a compound that inhibits cholinesterase in the central nervous system, and can be used in the treatment of neurodegenerative diseases (E.g. senile dementia and Alzheimer's disease).